Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.

Technology Evaluation Center Assessment Program. Executive summary - 1 Nov 2007

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to DNA Mutational Analysis
Share to DNA, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Treatment Outcome

Source

Identifiers

PMID: 18080406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.PMID 18080406Read ↗

Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.Semantic proximity Read ↗

Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?Semantic proximity Read ↗

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsSemantic proximity Read ↗

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives.Semantic proximity Read ↗

Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.Semantic proximity Read ↗

EGFR mutations and EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

EGFR Mutations and Lung CancerSemantic proximity Read ↗

Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.Semantic proximity Read ↗

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.Semantic proximity Read ↗

Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor MutationsSemantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.